Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
2.510
UNCHANGED
Streaming Delayed Price
Updated: 11:48 AM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
February 01, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Invivyd, Inc. (IVVD) f/k/a Adagio Therapeutics, Inc.
February 01, 2023
From
Robbins LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) on Behalf of Investors
February 01, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
February 01, 2023
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
January 31, 2023
From
The Schall Law Firm
Via
Business Wire
IVVD INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
January 31, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
December 19, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
December 06, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
November 17, 2022
From
Invivyd
Via
GlobeNewswire
NASDAQ:IVVD Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
November 11, 2022
San Diego, CA -- (SBWIRE) -- 11/11/2022 -- Certain directors of Invivyd, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 09, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
October 24, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd, Inc. (NASDAQ:IVVD) Shareholder Notice: Investigation over Possible Violations of Securities Laws
October 17, 2022
San Diego, CA -- (SBWIRE) -- 10/17/2022 -- Invivyd, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
October 13, 2022
From
Invivyd
Via
GlobeNewswire
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
October 12, 2022
From
Invivyd
Via
GlobeNewswire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews David Hering CEO, Invivyd Inc.
October 03, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.